PL387051A1 - Nowy sposób wytwarzania soli 5-amino-2, 3-dihydroftalazyn-1, 4-dionu z metalami alkalicznymi i ich zastosowania w medycynie - Google Patents

Nowy sposób wytwarzania soli 5-amino-2, 3-dihydroftalazyn-1, 4-dionu z metalami alkalicznymi i ich zastosowania w medycynie

Info

Publication number
PL387051A1
PL387051A1 PL38705109A PL38705109A PL387051A1 PL 387051 A1 PL387051 A1 PL 387051A1 PL 38705109 A PL38705109 A PL 38705109A PL 38705109 A PL38705109 A PL 38705109A PL 387051 A1 PL387051 A1 PL 387051A1
Authority
PL
Poland
Prior art keywords
dihydrophtalazine
medicine
amino
manufacturing
application
Prior art date
Application number
PL38705109A
Other languages
English (en)
Other versions
PL231885B1 (pl
Inventor
Musa Tazhudinovich Abidov
Admir Musaevich Abidov
Aleksei Silantievich Ishumratov
Vitakij Vilkin
Irina Georgievna Danilova
Original Assignee
Abidopharma Pl Spółka Z Ograniczoną Odpowiedzialnościąabidopharma Pl Spółka Z Ograniczoną Odpowiedzialnością
Abidov Musa TazhudinovichAbidov Musa Tazhudinovich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abidopharma Pl Spółka Z Ograniczoną Odpowiedzialnościąabidopharma Pl Spółka Z Ograniczoną Odpowiedzialnością, Abidov Musa TazhudinovichAbidov Musa Tazhudinovich filed Critical Abidopharma Pl Spółka Z Ograniczoną Odpowiedzialnościąabidopharma Pl Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL387051A priority Critical patent/PL231885B1/pl
Priority to US13/144,838 priority patent/US8536171B2/en
Priority to EP10705930.5A priority patent/EP2389364B1/en
Priority to EP16165549.3A priority patent/EP3072888A1/en
Priority to PCT/PL2010/000005 priority patent/WO2010082858A2/en
Publication of PL387051A1 publication Critical patent/PL387051A1/pl
Priority to US14/027,901 priority patent/US9101629B2/en
Publication of PL231885B1 publication Critical patent/PL231885B1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PL387051A 2009-01-16 2009-01-16 Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie PL231885B1 (pl)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PL387051A PL231885B1 (pl) 2009-01-16 2009-01-16 Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
US13/144,838 US8536171B2 (en) 2009-01-16 2010-01-15 Method for obtaining 5-amino 2,3-dihydrophthalazine-1,4-dione alkali metal salts and their use in medicine
EP10705930.5A EP2389364B1 (en) 2009-01-16 2010-01-15 New method for obtaining 5-amino-2,3-dihydrophthalazine-1,4-dione alkali metal salts and their use in medicine
EP16165549.3A EP3072888A1 (en) 2009-01-16 2010-01-15 Use of 5-amino-2,3-dihydrophthalazine-1,4-dione alkali metal salts in medicine
PCT/PL2010/000005 WO2010082858A2 (en) 2009-01-16 2010-01-15 New method for obtaining 5-amino-2,3-dihydrophthalazine-1,4-dione alkali metal salts and their use in medicine
US14/027,901 US9101629B2 (en) 2009-01-16 2013-09-16 Method for obtaining 5-amino-2,3-dihydrophthalazine-1,4-dione alkali metal salts and their use in medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL387051A PL231885B1 (pl) 2009-01-16 2009-01-16 Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie

Publications (2)

Publication Number Publication Date
PL387051A1 true PL387051A1 (pl) 2010-07-19
PL231885B1 PL231885B1 (pl) 2019-04-30

Family

ID=42062686

Family Applications (1)

Application Number Title Priority Date Filing Date
PL387051A PL231885B1 (pl) 2009-01-16 2009-01-16 Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie

Country Status (4)

Country Link
US (2) US8536171B2 (pl)
EP (2) EP2389364B1 (pl)
PL (1) PL231885B1 (pl)
WO (1) WO2010082858A2 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2542535E (pt) 2010-03-01 2014-08-25 Metriopharm Ag Formas cristalinas para sal de sódio de 5-amino-2,3-di hidroftalazino-1,4-diona, preparações farmacêuticas contendo o mesmo e processo para a produção das ditas formas
RU2532128C1 (ru) * 2013-05-22 2014-10-27 Закрытое акционерное общество "Управляющая компания "Световит" Способ получения о-люминолятов щелочных металлов
RU2577849C2 (ru) * 2013-09-25 2016-03-20 Общество с ограниченной ответственностью "Сэлвим" Бис(5-амино-1,4-диоксо-1,2,3,4-тетрагидрофталазин-2-ил)цинк, способ его получения, фармацевтическая композиция на его основе, лечебные средства на его основе, способ лечения кожных заболеваний и способ лечения гастрита
WO2016096143A1 (de) * 2014-12-18 2016-06-23 Metriopharm Ag Kristalline form von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
WO2017117586A1 (en) * 2015-12-31 2017-07-06 Bach Pharma, Inc. Compositions and nethods for treating brain dysfunction
CA3011766C (en) * 2016-02-16 2023-08-01 Metriopharm Ag Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione
EP3248602A1 (en) 2016-05-26 2017-11-29 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae
RU2625267C1 (ru) * 2016-09-22 2017-07-12 Общество с ограниченной ответственностью "АБИДАФАРМА" Способ производства нестерильных субстанций безводного "тамерита" и/или двухводного "галавита" - натриевых солей 5-амино-2,3-дигидрофталазин-1,4-диона (варианты) и способы дальнейшей их переработки в стерильные лекарственные препараты
WO2018082814A1 (en) 2016-11-07 2018-05-11 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis
EP3511325A1 (en) 2018-01-11 2019-07-17 MetrioPharm AG Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
US20210379063A1 (en) 2018-10-26 2021-12-09 Immunopharma Plus D.O.O. Oral aminodihydrophthalazinedione compositions and their use in the treatment of non-viral hepatitis
EP3858358A1 (en) 2020-01-31 2021-08-04 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases
EP3858328A1 (en) 2020-01-31 2021-08-04 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases
CN115768402A (zh) 2020-03-25 2023-03-07 麦翠奥制药公司 用于治疗急性肺损伤的5-氨基-2,3-二氢-1,4-酞嗪二酮
RU2744858C1 (ru) * 2020-04-28 2021-03-16 Межрегиональное общественное учреждение "Институт инженерной физики" Способ получения лиофилизата аминодигидрофталазиндион натрия - лекарственного препарата "Тамерон"
EP4164651B1 (en) 2020-06-10 2025-10-15 MetrioPharm AG 5-amino-2,3-dihydro-1,4-phthalazinedione for use in the treatment of coronaviral infections
EP3981405A1 (en) 2020-10-08 2022-04-13 MetrioPharm AG Compound for the treatment of coronaviral infections
PH12022553236A1 (en) 2020-07-09 2024-02-12 Metriopharm Ag Glucocorticoid-sparing agent
US20240075029A1 (en) 2020-12-02 2024-03-07 Metriopharm Ag Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection
RU2756568C1 (ru) * 2021-03-24 2021-10-01 Акционерное общество "Щелково Агрохим" Способ получения натриевой соли 5-амино-2,3-дигидро-1,4-фталазиндиона в гидратированной или безводной форме
EP4193994A1 (en) 2021-12-08 2023-06-14 MetrioPharm AG Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections
EP4209219A1 (en) 2022-01-07 2023-07-12 MetrioPharm AG Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione
EP4248963A1 (en) 2022-03-25 2023-09-27 MetrioPharm AG Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a fumaric acid ester
EP4483879A1 (en) 2023-06-29 2025-01-01 MetrioPharm AG 5-amino-2,3-dihydro-1,4-phthalazinedione for the prophylaxis and treatment of thrombotic disorders
WO2025067689A1 (en) 2023-09-26 2025-04-03 Metriopharm Ag 5-amino-2,3-dihydro-1,4-phthalazinedione for the treatment of infections with an rna virus
PL448122A1 (pl) * 2024-03-27 2025-09-29 Uniwersytet Jagielloński Sposób syntezy luminolu

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH683966A5 (it) 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanze attive in agenti anti-ipossici e di difesa.
RU2113222C1 (ru) 1997-09-30 1998-06-20 Закрытое акционерное общество "Центр современной медицины "Медикор" Иммуномодулирующее средство
RU2138264C1 (ru) 1999-05-06 1999-09-27 Абидов Муса Тажудинович Способ получения лекарственного препарата галавит
EP1203587B1 (en) * 2000-03-28 2010-07-14 Abidov, Musea Tazhudinovich A medicament and method for the production thereof
RU2169139C1 (ru) 2000-08-02 2001-06-20 Закрытое акционерное общество "Центр современной медицины "Медикор" Способ получения щелочных и щелочноземельных солей 5-амино-2,3-дигидро-1,4-фталазиндиона
RU2223227C2 (ru) 2001-08-10 2004-02-10 Уральский электрохимический комбинат Установка для испарения гексафторида урана
RU2222327C2 (ru) 2002-03-22 2004-01-27 Общество с ограниченной ответственностью "Абидофарма" Способ получения лекарственного препарата
US7326690B2 (en) 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
RU2233161C1 (ru) 2003-04-18 2004-07-27 Общество с ограниченной ответственностью "Абидофарма" Лекарственный препарат (варианты) и способ его производства
US8592421B2 (en) * 2003-08-04 2013-11-26 Valery Khazhmuratovich Zhilov Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
RU2312663C1 (ru) * 2006-02-21 2007-12-20 Закрытое акционерное общество "Центр современной медицины "Медикор" Способ лечения острого деструктивного панкреатита
RU2320345C1 (ru) * 2006-07-19 2008-03-27 ГУ Научно-исследовательский институт психического здоровья Томского научного центра Сибирского отделения Российской академии медицинских наук Способ лечения больных герпетиформной экземой капоши при формировании конверсионного расстройства
WO2010036711A1 (en) 2008-09-23 2010-04-01 Bach Pharma Inc. Methods of modulating protein homeostasis, metabolic syndrome, heavy metal intoxication and nrf2 transcription factors

Also Published As

Publication number Publication date
US8536171B2 (en) 2013-09-17
US20140113902A1 (en) 2014-04-24
PL231885B1 (pl) 2019-04-30
EP2389364A2 (en) 2011-11-30
EP2389364B1 (en) 2016-10-26
WO2010082858A3 (en) 2010-11-04
WO2010082858A2 (en) 2010-07-22
US20110275642A1 (en) 2011-11-10
EP3072888A1 (en) 2016-09-28
US9101629B2 (en) 2015-08-11

Similar Documents

Publication Publication Date Title
PL387051A1 (pl) Nowy sposób wytwarzania soli 5-amino-2, 3-dihydroftalazyn-1, 4-dionu z metalami alkalicznymi i ich zastosowania w medycynie
GB2470483B (en) Improvements in the management of medical tubing
GB2474364B (en) Hairbrush, methods of use, and methods of manufacturing the same
ZA201200882B (en) Medical supplies and method of producing the same
PL2536778T3 (pl) Sposób wytwarzania węglanopolioli polieterowych za pomocą katalizatorów typu podwójnego cyjanku metalu i w obecności soli metali
HRP20130392T1 (hr) Kateter koji sadrži kompozitnu vodilicu i postupci za uporabu i njegovu proizvodnju
AP2011005943A0 (en) Atropisomers of 2-purinyl-3-tolylquinazolinone derivatives and methods of use.
GB0921528D0 (en) Carbon and its use in blood cleansing applications
SI2279276T1 (sl) Nerjavni jekleni proizvod, uporaba proizvoda in postopek njegove izdelave
EP2367866A4 (en) POLYESTER, MANUFACTURING METHOD THEREFOR AND USE
ZA201104896B (en) Defining simple and complex animations
GB201108964D0 (en) Medicament and method of diagnosis
PL2393948T3 (pl) Sposób wytwarzania stopów metali alkalicznych i metali ziem alkalicznych oraz zastosowanie stopów metali alkalicznych i metali ziem alkalicznych
IL212672A (en) Cycloandesdepsipeptide compounds and their use in drug production
GB0920258D0 (en) New medical agents and use thereof
ZA201206740B (en) Aildenafil citrate crystal form o,preparation method and use thereof
IL215980A (en) An intermediate substance of Artemnam, a preparation containing it and methods for its preparation
PL2501380T3 (pl) Powolny wlew sulkardyny i jej soli
GB2488494B (en) Solution, use and method of preparation thereof
ZA201203286B (en) Therapeutic and diagnostic applications against trypanosomosis
ZA201106884B (en) Process for the preparation of doxazosin and salts thereof
GB201013829D0 (en) Human in vitro model of the blood cerebrospinal fluid barrier
PL2491021T3 (pl) Nowe acylopiperazynony i ich zastosowanie jako środki farmaceutyczne
EP2350212A4 (en) POLYAMINO-ACETONITRILES, PROCESSES FOR PREPARING THEM AND USE THEREOF
GB0909380D0 (en) Method and use